Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial-Reference-Cited by-同舟云学术

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Published:2016-02-08 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Gong Jifang,Liu Tianshu,Fan Qingxia,Bai Li,Bi Feng,Qin Shukui,Wang Jinwan,Xu Nong,Cheng Ying,Bai Yuxian,Liu Wei,Wang Liwei,Shen Lin

Funder

National Natural Science Foundation of China

National High Technology Research and Development Program

Beijing Municipal Science & Technology Commission Program

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2092-9

Reference20 articles.

1. Bang YJ, Van Cutsem E, Feyereislova A, Feyereislova A, Chung HC, Shen L, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

2. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.

3. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.

4. Okines A, Norman A, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529–34.

5. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer;World Journal of Gastrointestinal Oncology;2024-09-15

2. Gastrointestinal Cancer Therapy and Cardiotoxicity;Current Treatment Options in Oncology;2024-08-05

3. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report;World Journal of Clinical Cases;2024-02-06

4. ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications;Cancers;2023-12-18

5. Eficacia y tolerancia del tratamiento perioperatorio con esquema FLOT en pacientes con adenocarcinoma gástrico y la de unión gastroesofágica, tratados en el Hospital Italiano de buenos aires;Oncología Clínica;2023-12-15